Solid Biosciences Inc. (NASDAQ:SLDB) Short Interest Update

Solid Biosciences Inc. (NASDAQ:SLDB) was the recipient of a significant decline in short interest during the month of January. As of January 15th, there was short interest totaling 8,602,169 shares, a decline of 14.2% from the December 31st total of 10,029,089 shares. Based on an average daily volume of 1,147,561 shares, the short-interest ratio is presently 7.5 days. Approximately 12.8% of the shares of the stock are short sold. Approximately 12.8% of the shares of the stock are short sold. Based on an average daily volume of 1,147,561 shares, the short-interest ratio is presently 7.5 days.

Trending Headlines about Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Analyst backdrop remains constructive — the stock carries a consensus “Moderate Buy” with a materially higher average price target (~$14.70), which supports longer‑term demand and helps explain buying interest.
• Neutral Sentiment: Technical & ownership context is mixed — volume is modestly above average, the share price sits inside its 52‑week range ($2.41–$7.37) and the 50/200‑day moving averages are roughly $5.75/$5.71. Institutional ownership is high (~81%), which can both stabilize shares and limit volatility. Market Data
• Negative Sentiment: Coordinated insider selling is the main near‑term negative — multiple senior executives (CEO Alexander Cumbo, COO David Howton, CTO Paul Herzich, CFO Kevin Tan, plus other insiders) disclosed sales on Feb. 2 at an average price of $6.44. Disclosed sales total roughly 226k shares (≈$1.45M), with individual position trims in the ~20–25% range; that can weigh on sentiment and cap upside until the market digests the reasoning behind the disposals. Representative filings and writeups: InsiderTrades Article CEO SEC Filing

Insider Activity

In other news, insider Gabriel Brooks sold 28,335 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $6.44, for a total value of $182,477.40. Following the completion of the transaction, the insider directly owned 96,708 shares in the company, valued at approximately $622,799.52. This represents a 22.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jessie Hanrahan sold 26,535 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $6.44, for a total value of $170,885.40. Following the transaction, the insider directly owned 82,675 shares in the company, valued at approximately $532,427. This represents a 24.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 455,007 shares of company stock valued at $2,892,048. 13.63% of the stock is owned by insiders.

Institutional Trading of Solid Biosciences

A number of large investors have recently made changes to their positions in SLDB. Quantum Private Wealth LLC grew its position in Solid Biosciences by 3.9% in the 3rd quarter. Quantum Private Wealth LLC now owns 94,231 shares of the company’s stock worth $581,000 after purchasing an additional 3,500 shares during the period. Legal & General Group Plc grew its holdings in shares of Solid Biosciences by 208.6% in the second quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after acquiring an additional 4,063 shares during the period. Ameritas Investment Partners Inc. increased its position in Solid Biosciences by 205.5% during the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after acquiring an additional 4,534 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Solid Biosciences by 142.0% in the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock valued at $63,000 after acquiring an additional 5,991 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey boosted its position in Solid Biosciences by 233.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock worth $74,000 after purchasing an additional 10,585 shares during the last quarter. 81.46% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on SLDB shares. Chardan Capital reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Solid Biosciences in a research note on Tuesday, November 4th. Citigroup reaffirmed a “market outperform” rating on shares of Solid Biosciences in a research note on Wednesday, December 17th. Needham & Company LLC restated a “buy” rating and set a $16.00 target price on shares of Solid Biosciences in a report on Wednesday, January 14th. Barclays set a $9.00 target price on shares of Solid Biosciences and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Finally, Wall Street Zen downgraded shares of Solid Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, October 19th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Solid Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $14.70.

Solid Biosciences Trading Up 2.0%

Solid Biosciences stock traded up $0.13 on Tuesday, hitting $6.56. 220,728 shares of the stock traded hands, compared to its average volume of 1,005,595. Solid Biosciences has a 1 year low of $2.41 and a 1 year high of $7.37. The firm has a market cap of $511.09 million, a P/E ratio of -2.62 and a beta of 2.67. The business’s fifty day simple moving average is $5.75 and its 200 day simple moving average is $5.71.

Solid Biosciences (NASDAQ:SLDB) last released its earnings results on Monday, November 3rd. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). As a group, analysts predict that Solid Biosciences will post -2.84 earnings per share for the current year.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.